NCT03657238View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2018

Primary Completion Date

August 2, 2019

Study Completion Date

August 2, 2019

Conditions

Healthy

Interventions

DRUG

RD01

single S.C. dose of RD01 for subjects in test group

DRUG

Placebo

single S.C. dose of placebo for subjects in placebo group

Trial Locations (1)

Unknown

Xuan Wu Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

INDUSTRY

NCT03657238 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter